BioCentury
ARTICLE | Company News

CHMP's recommendations include Aimovig, Orphan candidates

June 1, 2018 2:44 PM UTC

Among a host of positive recommendations announced Friday, EMA's CHMP backed approval of migraine therapy Aimovig erenumab and Orphan Drug designees Tegsedi inotersen for hereditary transthyretin (TTR) amyloidosis and Myalepta metreleptin for leptin deficiency.

The committee recommended approval of Aimovig, a mAb that inhibits the calcitonin gene-related peptide (CGRP) receptor, to prevent migraine. CHMP said it would be the first mAb approved in the indication; FDA approved Aimovig last month. Novartis AG (NYSE:NVS; SIX:NOVN) holds the drug's EU rights under a deal with Amgen Inc. (NASDAQ:AMGN), which added $3.95 to $183.57 Friday...